Jason Springs, Endpoint Health CEO
Precision drug + diagnostics biotech scores modest Series A, retrofitting existing drug for new indication
A small biotech is going after sepsis — and it has raised some more money to advance that goal and get its newly-acquired drug into the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
